Bavarian Nordic is a biopharmaceutical company focused on the development and manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases.
Bavarian Nordic is committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Bavarian Nordic offers a challenging international working environment in which job satisfaction and personal growth have a high priority.
We are pioneering the next generation of cancer immunotherapies and vaccines for infectious diseases
MVA-BN® is the platform for IMVANEX®, an approved vaccine in Europe, and the poxvirus platform has been studied extensively for cancer treatment
We have built a revenue-generating biotech company with a late stage pipeline in blockbuster markets, strong IP, and manufacturing expertise
Our smallpox vaccine is the first approved in all European Union countries for use in the general population
Our late-stage product candidate has shown potential to extend the lives of prostate cancer patients